Aduro licenses immunomodulating cyclic dinucleotides to Novartis; terminated
Executive Summary
As Novartis AG integrates the massive oncology business it acquired last year from GlaxoSmithKline PLC for $14.5bn, its Novartis Institutes for BioMedical Research Inc. (NIBR) signed a multi-year agreement with Aduro Biotech Inc. in immuno-oncology. Novartis received ex-US rights to Aduro's preclinical cyclic dinucleotide (CDN) program.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice